Mark Peterson

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Vancouver's SimplyAsk.ai and Mexican telecom giant Axtel partner to tackle AI's high failure rate, aiming to unlock a multi-billion dollar market.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

Granted a tight deadline by Nasdaq, Triller Group must fix its finances and failing stock price or face delisting. Is its hybrid social media-fintech model viable?

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

An Amazon e-commerce firm is making a high-stakes leap into homeland security. Can new leadership and disruptive AI tech transform the company's future?

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

Sachem Capital's dividend announcement reveals a ~19% yield. We dissect the strategy of this mortgage REIT and its role as a disruptor in private lending.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.